InMed Pharmaceuticals (INM)
(Delayed Data from NSDQ)
$0.23 USD
0.00 (-0.09%)
Updated Sep 24, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
INM 0.23 0.00(-0.09%)
Will INM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for INM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INM
Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update
InMed (INM) Gets Grant to Begin Neurodegenerative Diseases Program
INM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for INM
InMed receives NASDAQ delisting notice
InMed Pharmaceuticals Faces Nasdaq Delisting Challenge
Micro-cap InMed Pharmaceuticals mentioned positively in Gene Online report
InMed Reports Promising Alzheimer’s Drug Study Outcomes
7 F-Rated Growth Stocks to Avoid Right Now: June 2024